BSD Medical is Now Pyrexar Medical

The complete line of BSD Hyperthermia products are availble thru Pyrexar Medical

Researchers are combining traditional cancer treatment therapies to increase a patient's chance of surviving cancer.  Even a few percentage points in tumor response can represent a significant benefit in saving a life. Dr. Niloy Datta. From Kantonsspital Aarau AG, Switzerland presented his recently published meta-analysis paper at a conference held at the Scientific-Research Institute of Oncology, St. Petersburg, Russia.

In the analysis, Dr. Datta compared results for treating advanced cancer of the cervix using combination therapies.  When comparing Chemotherapy with Radiotherapy (CTRT) versus radiation alone, the odds benefit of complete tumor response was 1.43.  When comparing Hyperthermia with Radiotherapy (HTRT) versus radiation alone, the odds of complete tumor response to 2.68.

Hyperthermia plus Radiation therapy provided superior outcomes without the increase in acute toxicity found with Chemotherapy.

 

Go to minute 25:00 on the presentation to see the overall Odds and risk ratios presented.

The paper was published on August 12th, 2016, in the International Journal of Hyperthermia, Hyperthermia, and radiotherapy with or without chemotherapy in locally advanced cervical cancer: a systematic review with conventional and network meta-analyses. Niloy R. Datta, Susanne Rogers, Dirk Klingbiel, Silvia Gómez, Emsad Puric & Stephan Bodis

We would like you to join us for the RSNA 102nd Scientific Assembly & Annual Meeting in Chicago.  RSNA (Radiological Society of North America) is the premier radiological show in the world, with more than 435 educational courses, 1,728 scientific paper presentations, and 659 exhibitors.

RSNA 2016 convenes radiology professionals from around the globe to gather knowledge through educational courses, explore the latest innovations presented by technical exhibitors, discover groundbreaking research from scientific paper presentations, and participate in networking opportunities.

The exhibits run Sunday thru Thursday, November 27th - December 1st. From the main entrance of the South Hall A, find your way to the back of the hall, next to the BISTRO food court.  Look for booth 3276.  Click the map for the full listing.

RSNA 2016, McCormick Place, Chicago Convention Center, Nov. 27th - Dec. 1st

RSNA 2016 floor map

 

If you would like to reserve some time in advance with one of our experts, submit the link form, and we will confirm your appointment time. We look forward to seeing you there.

 

 

 

DR. Zeljko VujaskovicZeljko Vujaskovic, MD, Ph.D., a hyperthermia proponent, and Pyrexar Hyperthermia systems “super user,” was presented with the J. Eugene Robinson Award. The award is presented annually to those how have made outstanding contributions to hyperthermic oncology. Dr. Vujaskovic, a professor of radiation oncology at the University of Maryland School of Medicine and the director of the Division of Translational Radiation Sciences at the University, is the twenty-seventh recipient of this honor.

There has been a resurgence in focus int the field of Thermal Oncology in the past year.  Many researchers are looking at hyperthermia as an effective immune system activator. Not only boosting the biological effective dose of radiation and increasing the effectiveness of drug delivery but as a way to keep cancer from returning to those patients who have already battled the disease.

Dr. Vujaskovic was recently a featured speaker at this year's Pyrexar Day. His complete presentation is available for review below.

 

If you want irrefutable proof that hyperthermia works, visit the US National Library of Medicine's website PubMed.gov, a division of the National Institute of Health (NIH).  PubMed is a repository of over 26 million citations for biomedical literature.  Using the search bar, type in “hyperthermia cancer treatment,” and you will find over 25,000 results.

Too many results than most of us would find useful, so we narrowed down the list.  The link below contains completed randomized trials using hyperthermia as an adjunct to radiation therapy and chemotherapy over the last 30 years.  The studies reveal a higher tumor response when hyperthermia is added over chemotherapy and radiotherapy alone.  Several of the studies use Pyrexar Medical equipment or lab built equipment using the same or similar radiofrequency energy delivery system.

abstract table

So the next time someone challenges you with “where is the evidence that hyperthermia works?” send them to evidence.pyrexar.com and let them read it for themselves.